<DOC>
	<DOCNO>NCT00009932</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness combine fenretinide , paclitaxel , cisplatin treat patient solid tumor respond previous therapy .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose , clinical toxicity , recommend phase II dose fenretinide combine paclitaxel cisplatin patient refractory solid tumor . - Determine pharmacokinetics regimen patient . - Determine therapeutic response regimen patient . OUTLINE : This dose escalation , multicenter study fenretinide . Patients receive oral fenretinide twice daily day 1-7 paclitaxel IV 3 hour follow cisplatin IV 2 hour day 2 . On day 8 course 1 , patient also receive fenretinide morning . Treatment repeat every 3 week maximum 8 course absence disease progression unacceptable toxicity . Patients achieve complete response receive 2 additional course . Cohorts 3-6 patient receive escalate dos fenretinide maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 3-24 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven refractory solid tumor paclitaxel cisplatin reasonable therapeutic option No active CNS disease CNS metastasis allow measurable disease outside CNS patient complete recovered 1 prior course CNS radiotherapy ( clinically indicate ) PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 OR Zubrod 02 Life expectancy : Not specify Hematopoietic : Platelet count least 100,000/mm3 Absolute neutrophil count least 1,500/mm3 Hepatic : Bilirubin great 2.0 mg/dL ALT AST great 2.5 time upper limit normal ( ULN ) ( 5 time ULN relate liver metastasis ) Renal : Creatinine great 1.5 mg/dL Cardiovascular : No severe symptomatic cardiac disease Other : No clinically significant/evident retinopathy No malignancy within past 5 year except localized nonmelanoma skin cancer carcinoma situ cervix No uncontrolled infection No significant medical psychiatric condition would increase risk Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 month , , least 2 month study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No prior paclitaxel , cisplatin , fenretinide At least 4 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy site measurable/evaluable disease No prior radiotherapy 25 % bone marrow Surgery : At least 2 week since prior therapeutic surgery recover Other : At least 4 week since prior routine vitamin A least 10,000 IU/ day beta carotene least 10 mg/day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2002</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>